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Anthelmintic resistance in equine cyathostomins is both widespread and highly prevalent in the benzimidazole
and tetrahydropyrimidine classes; however, reports of resistance to macrocyclic lactone (ML) drugs are sparse
and sporadic. This study reports a case of clear ML resistance in a group of Thoroughbred yearlings imported
from Ireland to the US in 2019. Fecal egg count reduction (FECR) following ivermectin administered in February
2020 demonstrated 100% reduction in the US bred yearlings, but 93.5%, 70.5%, and 74.5% reduction in three
groups of the imported yearlings. The two former groups were then retreated with ivermectin, yielding FECRs of
33.8% and 23.5%, respectively. Horses from these two groups were then assigned randomly to two possible
treatments; moxidectin or a triple combination of moxidectin, oxibendazole, and pyrantel pamoate. The groups
treated with moxidectin had FECRs of 90.2%, 57.3%, and 50.0%, while the triple combination had a 100% FECR
in all treated groups. Subsequently, the efficacy of ivermectin was reassessed in June 2020 yielding FECRs of
99.8%, 87.7%, and 62.0% in the three imported groups. The FECRs of the US bred yearlings all remained in the
99–100% range. This is the first study to clearly demonstrate ML resistance in cyathostomins and to confirm the
suspicion through reassessment. These data demonstrate that ML-resistant cyathostomins were imported from
Ireland and serve to illustrate that the global movement of horses has the potential to quickly spread ML-resistant
parasite isolates around the world. The equine industry is strongly encouraged to routinely monitor anthelmintic
efficacy, so occurrence of ML resistant cyathostomins can be detected and appropriate interventions imple
mented as early as possible.

1. Introduction
Equine cyathostomin parasites are ubiquitous in grazing horses
across the world, and anthelmintic resistance is widely documented to
two of three available drug classes (Kaplan 2002; Peregrine et al., 2014).
Despite early predictions of resistance developing to macrocyclic lactone
(ML) anthelmintics (e.g., ivermectin, moxidectin) in cyathostomins
(Sangster, 1999), to date there have been very few reports published.
The first report of ML resistance was a conference abstract reporting
reduced efficacy of moxidectin in donkeys kept at a donkey sanctuary
(Trawford et al., 2005). However, the donkeys were treated in an
extra-label manner using oral administration of an injectable formula
tion registered for ruminants, leading to questions as to the level of
evidence and the clinical significance to horses. The next report was in a
herd of Thoroughbred horses in Brazil (Molento et al., 2008), where

treatment with ivermectin, abamectin and moxidectin all yielded
reduced efficacies. Since then, a very limited number of studies, all of
which were multiple-farm surveys, have reported macrocyclic lactone
resistance in the form of reduced fecal egg count reduction at two weeks
following administration (Traversa et al., 2009; Milillo et al., 2009;
Näreaho et al., 2011; Canever et al., 2013; Relf et al., 2014). This is
remarkable given that ML anthelmintics have been the most widely
administered drugs in horses by far over the past several decades
(Stratford et al., 2014; Becher et al., 2018). It is also noteworthy that the
reports published, thus far, are from Europe (4) and Brazil (1), but so far
none have been published from North America, despite a remarkably
high anthelmintic treatment intensity, especially in the Thoroughbred
industry (Robert et al., 2015). Furthermore, these reports were all
limited to single farms/populations, most often due to a single or very
few horses within the treated groups exhibiting a decrease in fecal egg
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count reduction, and in none of these studies were horses re-treated to
confirm the suspicion of ivermectin resistance. Thus, the currently
available data on ML resistance in cyathostomin populations is scarce
and mostly inconclusive. Truly convincing evidence with follow-up
confirmation of full-fledged resistance to ML anthelmintics in cyathos
tomins has yet to be presented.
Despite the limited evidence, it is generally believed that ML

resistance is emerging in cyathostomin populations. This is supported by
several reports of shortened egg reappearance periods (ERPs) following
administration of this drug class. Originally, ERPs were reported in the
9–13 week range for ivermectin (Borgsteede et al., 1993; Boersema
et al., 1996; Demeulenaere et al., 1997), while moxidectin was capable
of suppressing strongyle egg shedding for 16–22 weeks (Jacobs et al.,
1995; DiPietro et al., 1997; Demeulenaere et al., 1997). However, in the

Fig. 1. Flow diagram describing the series of events for the study population consisting of yearlings born in either Kentucky, USA (yellow) or Ireland (green) in 2019.
The Irish yearlings were imported to the US in October 2019. The flowchart indicates when horses received anthelmintic treatment and what they were treated with.
The triple anthelmintic treatment administered in April 2020 consisted of moxidectin, oxibendazole, and pyrantel pamoate. (For interpretation of the references to
colour in this figure legend, the reader is referred to the Web version of this article.)
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past fifteen years, there have been multiple reports of significantly
shortened ERPs (von Samson-Himmelstjerna et al., 2007; Relf et al.,
2014; Geurden et al., 2014; Molena et al., 2018) and in some cases as
short as four weeks for both MLs (Lyons et al., 2008, 2011; Bellaw et al.,
2018). Terminal studies performed at the University of Kentucky have
demonstrated that for ivermectin, the shortened ERP appears to be due
to resistance at the luminal L4 stage with efficacy levels often well below
50% (Lyons et al., 2009; Lyons and Tolliver, 2013). However, with
moxidectin the pattern is less clear as the efficacy against luminal L4s
was still above 96% in cyathostomin populations with 4-week ERPs
(Lyons et al., 2010; Bellaw et al., 2018). Taken together, while the
multiple reports of shortened ERP may be indicative of emerging resis
tance, more data are needed to fully understand the possible
mechanisms.
In this report, we present a case of unequivocal ML treatment failure
in a group of Thoroughbred yearlings imported to the US from a farm in
Ireland. We describe how the lack of efficacy was confirmed through
rigorous testing, and describe the treatment and management decisions
made on the farm to mitigate the situation.

a triple combination of oxibendazole (10 mg/kg, Anthelcide, Zoetis,
New Jersey, USA), pyrantel pamoate (6.6 mg/kg, Strongid P, Zoetis,
New Jersey, USA), and moxidectin (400 μg/kg, Quest, Zoetis, New
Jersey, USA). Following this, all yearlings were treated again with
ivermectin (200 μg/kg, Zimecterin, Boehringer-Ingelheim, Ingelheim,
Germany) on June 8, 2020 to verify the reduced efficacy observed in
February.
2.4. Fecal egg counts
Fecal samples were collected either rectally or from samples freshly
deposited on stall floors, were put in airtight containers, kept refriger
ated, and analyzed within one working week. All post-treatment samples
were collected at 14 days following anthelmintic administration.
Strongyle fecal egg counts (FEC) were performed by farm personnel
using the OvaTector system (BG Medical Products Inc, Venice, Florida,
USA) with a multiplication factor of 10 eggs per gram (EPG) and sodium
nitrate (specific gravity 1.25) as flotation medium.
2.5. Statistical analysis

2. Materials and methods

Fecal egg count reductions (FECRs) were calculated for each treat
ment and group using an online web interface providing a Bayesian
hierarchical model analysis of the data with estimation of mean FECR
and 95% Credible Interval (Torgerson et al., 2014; Wang et al., 2018).
Resistance was suspected whenever the group mean FECR fell below
95% and the lower Credible Interval fell below 90%.
The FECR data were analyzed using SAS version 9.4 (Cary, NC, USA).
Data were evaluated for normal distribution with Shapiro-Wilk and
Kolmogorov-Smirnov statistics as well as normal probability plots, and
were log-transformed to achieve normal distribution. A mixed linear
model was constructed for the ivermectin FECR data (treatments A and
C) with time point and group as class variables. The ‘mixed’ procedure
was used with repeated measures across the two time points and horse
ID as random effect. Analyses analyzed for differences between groups
and time points as well as the effect of the interaction term between
group and time point. In one set of analyses, the group variable was
replaced by country of origin (USA or Ireland) to analyze for associated
trends. Whenever any of the covariates was found significant, a Tukey’s
pair-wise comparison of the adjusted least squares means was per
formed. All analyses were interpreted at the α = 0.05 level.

2.1. Horses
The data presented herein were obtained from a Thoroughbred
operation in Central Kentucky. This farm breeds a large number of foals
every year, but also imports a contingency of weanlings from Europe
every autumn. Following current recommendations, the farm has
implemented routine monitoring of parasite egg count levels and
anthelmintic treatment efficacy.
The study population consisted of two groups of Thoroughbred
yearlings born in 2019 and all kept at the same farm in Kentucky, USA.
One group (25 fillies and 33 colts) were born in Ireland and were im
ported into the US on October 24, 2019. The other group (26 fillies and
29 colts) were born on the US farm. The horses were organized in six
groups (Fig. 1), which were kept separate from each other with no
overlap in use of paddocks, pastures or barns. As per the usual procedure
on Kentucky Thoroughbred farms, many of the yearlings were sold in the
traditional yearling sales in September 2020. Regardless of ownership,
the horses were then placed into training for the 2021 season.
2.2. Treatment history

3. Results

Prior to weaning, foals at the farm in Ireland were dewormed with
fenbendazole at 2 and 5 months of age. Post weaning, they were treated
with ivermectin at 6 months and moxidectin at 7 months of age prior to
exporting them to the US. The US born population was dewormed with a
combination of piperazine and fenbendazole at 2 and 4 months of age,
followed by ivermectin at 5 and 7 months of age.

Results are presented for each of the six groups, three of which were
US bred and three that were imported from Ireland.
The three US bred groups (1, 2, 3) were each dewormed with iver
mectin on two occasions four months apart, and the FECRs were all in
the 99–100% range (Table 1). The ivermectin FECRs from the imported
yearlings (groups 4, 5, 6) are reported in Table 2. All three imported
groups demonstrated reduced ivermectin efficacy. Additionally, group
6, which was the only group where efficacy was monitored following the
November 2019 moxidectin treatment, yielded reduced efficacy there as
well (Table 3). Overall, there were no significant differences in FECR
between the February and June ivermectin treatments (p = 0.839), but
there were significant differences between groups (p < 0.001) with
group 6 demonstrating a significantly lower FECR than groups 1–4.
There was a significant association between FECR and the interaction
term between group and time point (p < 0.001) with group 6 having a
significantly lower FECR than all other groups for the June treatment.
The analysis with the country of origin variable revealed significantly
lower FECRs in the Irish yearlings (p < 0.001) but no difference between
the two treatment time points (p = 0.893). The follow-up treatments
administered on February 28 in Groups 3 and 4 both demonstrated a
pronounced lack of reduction, and the June 8 ivermectin treatment
yielded reduced efficacy in two of the three groups. Table 3 presents the

2.3. Treatments administered
The course of events and the timing of anthelmintic treatments are
outlined in the flow diagram in Fig. 1. All horses were weighed on
electronic scales on a monthly basis and anthelmintic products were
administered orally according to weight.
All horses were administered moxidectin (400 μg/kg, Quest Plus,
Zoetis, New Jersey, USA) on November 25, 2019, and ivermectin (200
μg/kg, Equimax, Bimeda, Illinois, USA) was administered to all yearlings
on February 6, 2020. Given a lack of fecal egg count reduction observed
among the imported yearlings following these moxidectin and iver
mectin treatments, Groups 4 and 5 were re-treated 21 days later on
February 28, 2020 and FEC repeated 14 days following treatment.
Subsequent to this, the colts in Groups 4 and 5 were allocated randomly
to two treatment groups; one group was administered moxidectin (400
μg/kg, Quest, Zoetis, New Jersey, USA) and the other was administered
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results of treating the imported yearlings with either moxidectin alone
or the triple combination. Moxidectin efficacy was reduced in all three
groups, but the triple combination demonstrated a 100% FECR.

Table 1
Strongyle fecal egg counts presented in eggs per gram of feces (EPG) in three
groups of US-bred Thoroughbred yearlings and the percent reduction with 95%
credible intervals (CI) following oral administration of ivermectin (200 μg/kg)
on two separate occasions.a
Datea

N

Pre-treatment (EPG)

Post-treatment (EPG)

Mean

Range

Mean

Range

12
16

1142.5
868.2

530–2070
310–1910

0
0

-

100% (99.8–100)
100% (99.7–100)

10
12

1347.0
1116.7

720–2640
320–1840

0
10.8

0–60

100% (99.8–100)
99.4% (97.6–100)

24
26

1236.0
1239.2

610–1720
170–2090

0.5
0

0–60
-

100% (99.8–100)
100% (99.9–100)

4. Discussion

FECR (95% CI)

The data presented herein are remarkable in at least three ways.
First, this is the most comprehensive data set demonstrating reduced ML
efficacy against equine cyathostomins reported to date. Second, reduced
efficacy was demonstrated to both ivermectin and moxidectin, and the
suspicion of resistance was confirmed through re-testing. Third, the high
efficacy of the ivermectin treatments in all three groups of US bred
horses measured concomitantly with the reduced efficacy in the Irish
bred horses demonstrates that the drugs were of high quality, adminis
tered correctly by farm personnel, and that the reduced efficacy was not
a result of laboratory error. These data present clear evidence that the
cyathostomin population harbored by the US bred horses were suscep
tible to ivermectin, whereas the parasites of the Irish imports were
resistant to both ivermectin and moxidectin. As these populations were
kept completely separate throughout the study, this is clear evidence
that the ML resistant parasites were imported from the Irish farm.
An earlier equine anthelmintic resistance survey indicated that
anthelmintic resistance levels were more pronounced in Kentucky than
other southern states, and these levels were among the highest reported
anywhere in the world (Kaplan et al., 2004). The use of anthelmintics on
Kentucky Thoroughbred farms is very intense, with the large majority of
farms deworming their yearlings six times a year or more (Robert et al.,
2015). Thus, it was always the expectation that ML-resistant cyathos
tomins were very likely to eventually occur in the heart of Thoroughbred
country in Kentucky. In light of this, it is a genuine surprise that the first
case of full-fledged ML resistance was diagnosed in horses imported
from Ireland. A recent survey conducted in Ireland documented that
parasite control programs adopted by the equine industry there
(including Thoroughbred farms) were not following current recom
mendations, with little or no diagnostic monitoring of parasite presence
and treatment efficacy, and frequent administration of anthelmintic
treatments with heavy reliance on ML products (Elghryani et al., 2019).
Thus, several similar risk factors for development of ML resistance were
also present in Ireland. Nonetheless, it is important to note that the
Kentucky farm has imported weanlings from Ireland every year for the
past several years, and that routine testing in previous years had always
demonstrated full ML efficacy. Furthermore, the anthelmintic treatment
regimen practiced on the Ireland facility with two benzimidazole
treatments targeting ascarid parasites followed by two ML treatments
directed at the strongyle parasites is in line with general recommenda
tions, and cannot be considered overly excessive compared with general
trends within the Thoroughbred industry. Thus, it is not possible to
identify what set of conditions and circumstances led this particular
cyathostomin population to become resistant, or why it occurred now.
The heavy reliance on ML anthelmintics for equine strongyle control
is obviously problematic, but the industry is left with little choice. In
cyathostomins, anthelmintic resistance is widespread to both the benz
imidazoles and pyrimidines (Peregrine et al., 2014), often leaving the
MLs as the only viable treatment option. This is reflected by current
guidelines for equine parasite control, wherein it is recommended to
primarily use MLs for strongyle control and only use other drug classes if
pertinent testing has demonstrated good efficacy (Nielsen et al., 2019;
ESCCAP 2019; Rendle et al., 2019). While ML resistance has been
remarkably slow to progress in cyathostomins, the data presented herein
clearly demonstrate that a resistance break-through can happen, and
likely is occurring elsewhere as well. It is noteworthy that the degree of
parasite egg count monitoring adopted by this farm is well above in
dustry norms. As is most common with cyathostomin infections, the
horses infected with the ML-resistant parasites were all clinically
normal; consequently, the ML resistance was discovered here only due
to this monitoring program. Other equine operations in the US, Ireland,

Group 1
A
C
Group 2
A
C
Group 3
A
C
a

Ivermectin treatments administered on A: February 6 and C: June 8, 2020.

Table 2
Strongyle fecal egg counts presented in eggs per gram of feces (EPG) and percent
reduction with 95% credible intervals (CI) in three groups of yearling Thor
oughbreds imported from Ireland following oral ivermectin administration (200
μg/kg) on three separate occasions.a
Datea

N

Pre-treatment (EPG)

Post-treatment
(EPG)

FECR (95% CI)

Mean

Range

Mean

Range

10
8
15

1317.0
131.3
1605.3

620–1970
10–320
10–2680

105.0
118.9
4.0

0–320
0–350
0–20

93.5% (85.6–97.6)
33.8% (13.4–61.9)
99.8% (99.4–99.9)

16
16
18

968.1
348.8
1278.9

550–1720
20–1170
210–2460

348.8
358.1
174.1

20–1170
20–760
0–670

70.5% (55.5–88.9)
23.5% (12.6–45.0)
87.7% (79.6–93.1)

19
25

1080.0
1246.3

510–1980
470–2490

332.6
570.0

20–880
10–1490

74.5% (62.4–83.2)
62.0% (48.3–72.4)

Group 4
A
B
C
Group 5
A
B
C
Group 6
A
C

a
Ivermectin treatments administered on A: February 6, B: February 28, and C:
June 8, 2020.

Table 3
Strongyle fecal egg counts and percent reduction with 95% credible intervals
(CI) in three groups of yearling Thoroughbreds imported from Ireland following
either an oral administration of a triple combination (T) consisting of moxidectin
(400 μg/kg), pyrantel pamoate (6.6 mg/kg) and oxibendazole (10 mg/kg) or a
single dose of moxidectin (M, 400 μg/kg).
N

Pre-treatment EPG

Post-treatment EPG

Mean

Range

Mean

Range

FECR (95% CI)

336.0
80.0

320–350
10–160

0
5.0

0–20

100% (76.2–100)
90.2% (62.6–98.2)

313.3
385.7

20–760
180–720

0
250.0

20–760

100% (98.6–100)
57.3% (26.1–78.6)

1229.4

570–2060

638.8

180–1180

50.0% (30.7–64.2)

Group 4
Ta
Ma

2
5

Group 5
Ta
Ma

9
7

Group 6
Mb
a
b

16

Treatments administered on April 10, 2020.
Treatment administered on November 25, 2019.
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and elsewhere, most likely already have ML resistant cyathostomins
without being aware due to a lack of testing and the relatively low
pathogenicity of cyathostomins. This case clearly illustrates the impor
tance of quality routine FECR testing, which immediately informed the
farm manager of the situation and allowed him to react in time by
keeping the populations completely separate, thereby avoiding an
introduction of the resistant parasites to the entire facility.
The triple combination of oxibendazole, pyrantel pamoate and
moxidectin was administered in an attempt to achieve the desired 100%
reduction in FEC. We expected that the moxidectin efficacy would be
somewhat higher than that for ivermectin, given the higher dose and
lipophilic properties of this molecule. However, this was not observed,
as the 95% CI for FECR overlapped for both drugs. Although the effi
cacies of oxibendazole and pyrantel pamoate were not tested separately
in these horses, the 100% reduction in FEC of the combination suggests
that one or both of these drugs were reasonably or highly effective.
However, high efficacy for these two drugs is unlikely on Kentucky
Thoroughbred farms, as resistance to benzimidazoles and pyrimidines is
highly prevalent (Kaplan et al., 2004). Consequently, using the triple
combination to treat ML resistant cyathostomins in Kentucky is unlikely
to be a sustainable treatment choice over time. We recently demon
strated that use of a combination of oxibendazole and pyrantel pamoate
against a cyathostomin population with documented resistance to both
classes was not efficacious (Scare et al., 2018). Thus, if a triple combi
nation treatment is used, the efficacy will need to be closely monitored;
once this approach loses efficacy we will have run out of treatment
options. The pharmaceutical industry has not introduced any new
anthelmintic classes with new modes of action for equine usage since
ivermectin almost 40 years ago, and there are no indications that any
new anthelmintic classes will be introduced for horses in the foreseeable
future. The data presented herein strongly demonstrate that the port
folio of equine anthelmintics is woefully unsatisfactory, leaving
end-users with few viable treatment options and almost no alternatives,
when current options fail.
Some of these imported yearlings were sold at the 2020 September
yearling sales, while the majority were retained by the owner and sent
away for training. Thus, they likely brought their ML resistant cya
thostomins with them and would almost certainly be introducing these
to the new facilities. With a high degree of national and international
movement of horses and the general lack of quarantine testing, this
population of ML resistant worms will quickly spread to numerous lo
cations, and given the heavy reliance on ML anthelmintics across the
world, resistant populations will be quickly selected for. While this
outlook is scary, the fact that these yearlings are destined for a career as
race horses should mitigate the risk of spread, since they will go into
training and have little or no access to pasture for the next couple years.
Exceptions will be injured horses sent home for rehabilitation, situations
where horses are given a break from training to allow additional
maturation and growth, or horses that are retired from racing to become
off-the-track-Thoroughbreds in search of new careers as riding horses.
Thus, in a many of these horses, the cyathostomin infection may be
somewhat self-limiting. However, it should be kept in mind that
encysted cyathostomin larvae undergo arrested development at the
early third stage, which means that it can take several years for the
infection to be eliminated, even if effective adulticidal anthelmintics are
administered (Smith, 1976a, 1976b). Taken together, these yearlings are
likely to introduce ML resistant cyathostomins to their new facilities,
and despite the reduced levels of parasite transmission that are typical of
the management used for Thoroughbred horses in training, spread of
infection to other horses and properties is likely. Thus, it would be
pertinent to recommend quarantine testing of ML efficacy for any
yearlings newly acquired at a sale.
In conclusion, this study is the first in the world to confirm ML
resistance in a population of equine cyathostomins through a series of
repeated testing. We have presented data from a large study population
(58 and 55 horses in each group), and followed this population over an

eight-month period, conducting 19 different FECRTs for evaluation of
ivermectin, moxidectin, and the triple combination of oxibendazole,
pyrantel pamoate, and moxidectin. Furthermore, the study demon
strated that the isolate was imported to the US from Ireland, demon
strating how resistant parasites can quickly traverse continents and
quickly be spread globally. Equine operations are strongly encouraged
to heed this threat to equine health, and routinely monitor anthelmintic
efficacy on a yearly basis. Only by taking such actions will it be possible
to detect cases like these as early as possible and institute appropriate
interventions.
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